248588-33-2 Usage
General Description
1-(3-Fluoro-phenyl)-cyclopropanecarboxylic acid is a chemical compound with a cyclopropane ring and a carboxylic acid group attached to a phenyl ring containing a fluorine atom. It is used in the research and development of pharmaceuticals and agrochemicals due to its potential as a building block for the synthesis of novel compounds. The presence of the fluorine atom on the phenyl ring also makes it useful in medicinal chemistry for the design of fluorine-containing drugs. Additionally, the cyclopropane ring confers unique chemical reactivity, which can be exploited for the creation of diverse molecular structures. Overall, this compound has potential applications in various fields, including drug discovery and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 248588-33-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,8,5,8 and 8 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 248588-33:
(8*2)+(7*4)+(6*8)+(5*5)+(4*8)+(3*8)+(2*3)+(1*3)=182
182 % 10 = 2
So 248588-33-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H9FO2/c11-8-3-1-2-7(6-8)10(4-5-10)9(12)13/h1-3,6H,4-5H2,(H,12,13)
248588-33-2Relevant articles and documents
Preparation method of arylcyclopropane compound
-
Paragraph 0089-0093, (2022/01/10)
The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride
N-CYCLOALKYLGLYCINES AS HIV PROTEASE INHIBITORS
-
Page 49-50, (2010/02/07)
This invention relates generally to N-cycloalkylglycines of the Formula (I): or a stereoisomeric form, a mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits including the same, methods for using the same for treating viral infection or an assay standards or reagents, and intermediates and processes for making the same.